Lilly agrees to buy Icos for $2.1bn
Eli Lilly has entered into a definitive agreement to buy its biotech partner Icos in an all-cash deal. Lilly will pay $32 for each outstanding Icos share (a 21% premium to the 10-day pre-announcement market average), valuing the company at about $2.1bn.
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.